Latent Autoimmune Diabetes of Adulthood (LADA): A Commonly Misdiagnosed Condition as Type II Diabetes Mellitus

Srikanta Banerjee; Faton Bytyci

doi:7200177

While the awareness of Latent Autoimmune Diabetes of Adults (LADA) is growing, many of these individuals are still misdiagnosed as having Type II diabetes mellitus. Even though current treatment patterns may be similar, an autoimmune etiology may require a paradigm shift in the treatment protocol utilized for these patients. Biologic agents used against Rheumatoid Arthritis have also been proved to be effective against diabetes mellitus. The growing number of peer-reviewed articles in the professional literature is an indication of how individuals in the scholastic arena are expanding in the current body of knowledge. By dissemination of best practices, other health care practitioners can learn about the specific needs of this specific subgroup of patients with diabetes. The purpose of the literature review conducted here was to describe the status of the peer-reviewed literature over the past decade pertaining to LADA and raise awareness on biologic agent treatment methods that may be more appropriate than what is currently utilized. A literature search was conducted using the Cochrane, Medline, and PubMed daases. Inclusion criteria included publication date from January 1, 2006 through July 31, 2015, written in the English language, and a focus on Latent Autoimmune Diabetes of Adults as the primary discipline. Diabetes was searched as an overarching discipline; articles focused on sub-disciplines or other health professions disciplines were excluded. The search resulted in 235 articles. Each of the authors reviewed the abstracts for all articles and read full articles when necessary. The result was 10 articles that were then considered in depth. The articles were categorized according to their primary theme: interventions (N=2); pathophysiology (N=3); case study (N=2); LADA versus Type II Diabetes (N=3). Year of publication and journal were also examined. The results of the literature search lead to several observations about how the peer-reviewed literature has been used to date and how it could be used to advance the emerging ﬁeld of diagnosis and treatment of LADA. Additionally, the autoimmune component of LADA could be used to change scientists’ thinking about Type 2 Diabetes as well.

[1]

Appel, S., Wadas, T., Rosenthal, R., & Ovalle, F. (2009). Practice. Latent autoimmune diabetes of adulthood (LADA): an often misdiagnosed type of diabetes mellitus. Journal of the American Academy of Nurse Practitioners, 21(3), 156–159. http://doi.org/10.1111/j.1745-7599.2009.00399.x.

[2]

Brophy, S. (2011). Interventions for latent autoimmune diabetes (LADA) in adults. Cochrane Daase of Systematic Reviews, (9).

[3]

Guglielmi, C., Palermo, A., & Pozzilli, P. (2012). Latent autoimmune diabetes in the adults (LADA) in Asia: from pathogenesis and epidemiology to therapy. Diabetes/Metabolism Research and Reviews, 28 Suppl 2, 40–46. http://doi.org/10.1002/dmrr.2345.

[4]

Ludvigsson, J., Faresjö, M., Hjorth, M., Axelsson, S., Chéramy, M., Pihl, M., … Casas, R. (2008). GAD treatment and insulin secretion in recent-onset type 1 diabetes. The New England Journal of Medicine, 359(18), 1909–1920. http://doi.org/10.1056/NEJMoa0804328.

[5]

Lutgens, M. W. M. D., Meijer, M., Peeters, B., Poulsen, M.-L. N. F., Rutten, M. J., Bots, M. L., … Soedamah-Muthu, S. S. (2008). Easily obtainable clinical features increase the diagnostic accuracy for latent autoimmune diabetes in adults: an evidence-based report. Primary Care Diabetes, 2(4), 207–211. http://doi.org/10.1016/j.pcd.2008.08.003.

[6]

Stenström, G., Gottsäter, A., Bakhtadze, E., Berger, B., & Sundkvist, G. (2005). Latent Autoimmune Diabetes in Adults Definition, Prevalence, β-Cell Function, and Treatment. Diabetes, 54(suppl 2), S68–S72. http://doi.org/10.2337/diabetes.54.suppl_2.S68.

[7]

Sachdeva, N., Paul, M., Badal, D., Kumar, R., Jacob, N., Dayal, D., … Bhadada, S. K. (2015). Preproinsulin specific CD8+ T cells in subjects with latent autoimmune diabetes show lower frequency and different pathophysiological characteristics than those with type 1 diabetes. Clinical Immunology (Orlando, Fla.), 157(1), 78–90. http://doi.org/10.1016/j.clim.2015.01.005

[8]

Reghina, A. D., Florea, S., Constantin, M., & Fica, S. (2015). The Impact of Thyroid Autoimmunity on the Clinical and Diabetes Parameters of Patients with Latent Autoimmune Diabetes in Adults. Experimental And Clinical Endocrinology & Diabetes: Official Journal, German Society Of Endocrinology [And] German Diabetes Association.

[9]

El Baba, K., Zantout, M., & T. Azar, S. (2012). Polyglandular Autoimmune Syndromes. Current Immunology Reviews, 8(4), 263–267. http://doi.org/10.2174/157339512804806198.

[10]

Lu, J., Hou, X., Zhang, L., Hu, C., Zhou, J., Pang, C., … Jia, W. (2015). Associations between clinical characteristics and chronic complications in latent autoimmune diabetes in adults and type 2 diabetes. Diabetes/Meolism Research & Reviews, 31(4), 411–420. http://doi.org/10.1002/dmrr.2626.

[11]

Huang, G., Xiang, Y., Pan, L., Li, X., Luo, S., & Zhou, Z. (2013). Zinc transporter 8 autoantibody (ZnT8A) could help differentiate latent autoimmune diabetes in adults (LADA) from phenotypic type 2 diabetes mellitus. Diabetes/Meolism Research & Reviews, 29(5), 363–368. http://doi.org/10.1002/dmrr.2396.

[12]

Cabrera-Rode, E., Perich, P., Diaz-Horta, O., Tiberti, C., Molina, G., Arranz, C., … Dimario, U. (2002). Slowly progressing type 1 diabetes: persistence of islet cell autoantibodies is related to glibenclamide treatment. Autoimmunity, 35(7), 469–474.

[13]

Mastrandrea, L., Yu, J., Behrens, T., Buchlis, J., Albini, C., Fourtner, S., & Quattrin, T. (2009). Etanercept Treatment in Children With New-Onset Type 1 Diabetes Pilot randomized, placebo-controlled, double-blind study. Diabetes Care, 32(7), 1244–1249. http://doi.org/10.2337/dc09-0054.

[14]

Timper, K., Hruz, P., Beglinger, C., & Donath, M. Y. (2013). Infliximab in the Treatment of Crohn Disease and Type 1 Diabetes. Diabetes Care, 36(7), e90–e91. http://doi.org/10.2337/dc13-0199

[15]

Yazdani-Biuki, B., Wohlfahrt, K., Mulabecirovic, A., Mueller, T., Hermann, J., Graninger, W. B., … Brezinschek, R. I. (2004). Long term treatment of psoriatic arthritis with infliximab. Annals of the Rheumatic Diseases, 63(11), 1531–1532.

[16]

Rewers, M., & Gottlieb, P. (2009). Immunotherapy for the Prevention and Treatment of Type 1 Diabetes Human trials and a look into the future. Diabetes Care, 32(10), 1769–1782. http://doi.org/10.2337/dc09-0374.

[17]

Schloot, N. C., Meierhoff, G., Lengyel, C., Vándorfi, G., Takács, J., Pánczél, P., … Jermendy, G. (2007). Effect of heat shock protein peptide DiaPep277 on ß-cell function in paediatric and adult patients with recent-onset diabetes mellitus type 1: two prospective, randomized, double-blind phase II trials. Diabetes/Metabolism Research and Reviews, 23(4), 276–285. http://doi.org/10.1002/dmrr.707.

[18]

Ipadeola, A., Adeleye, J., O., & Akinlade, K., S. (2015). Latent autoimmune diabetes amongst adults with type 2 diabetes in a Nigerian tertiary hospital. Primary Care Diabetes, 9(3), 231–236. http://doi.org/10.1016/j.pcd.2014.09.003

[19]

Maddaloni, E., Lessan, N., Tikriti, A. Al, Buzzetti, R., Pozzilli, P., & Barakat, M. T. (2015). Latent Autoimmune Diabetes in Adults in the United Arab Emirates: Clinical Features and Factors Related to Insulin-Requirement. Plos One, 10(8), e0131837–e0131837. http://doi.org/10.1371/journal.pone.0131837.

[20]

Liu, L., Li, X., Xiang, Y., Huang, G., Lin, J., Yang, L., … Zhou, Z. (2015). Latent Autoimmune Diabetes in Adults With Low-Titer GAD Antibodies: Similar Disease Progression With Type 2 Diabetes: A Nationwide, Multicenter Prospective Study (LADA China Study 3). Diabetes Care, 38(1), 16–21. http://doi.org/10.2337/dc14-1770

[21]

Porcel Chacón, R., Tapia Ceballos, L., & Ranchal Pérez, P. (2015). [Latent autoimmune diabetes in the young. A new case]. Anales De Pediatría (Barcelona, Spain: 2003), 82(5), e238–e239. http://doi.org/10.1016/j.anpedi.2014.05.017

[22]

Aycan, Z., Berberoglu, M., Adiyaman, P., Ergür, A. T., Ensari, A., Evliyaoglu, O., … Ocal, G. (2004). Latent autoimmune diabetes mellitus in children (LADC) with autoimmune thyroiditis and Celiac disease. Journal of Pediatric Endocrinology & Meolism: JPEM, 17(11), 1565–1569.

[23]

Chen, J., Fontes, G., Saxena, G., Poitout, V., & Shalev, A. (2010). Lack of TXNIP protects against mitochondria-mediated apoptosis but not against fatty acid-induced ER stress-mediated beta-cell death. Diabetes, 59(2), 440–447. http://doi.org/10.2337/db09-0949.

[24]

Ramirez CE, Nian H, Yu C, et al. Treatment with Sildenafil Improves Insulin Sensitivity in Prediabetes: A Randomized, Controlled Trial. The Journal of Clinical Endocrinology & Metabolism. 2015; 100(12):4533-4540. doi:10.1210/jc.2015-3415.

[25]

Chen, J., Saxena, G., Mungrue, I. N., Lusis, A. J., & Shalev, A. (2008). Thioredoxin-interacting protein: a critical link between glucose toxicity and beta-cell apoptosis. Diabetes, 57(4), 938–944. http://doi.org/10.2337/db07-0715

[26]

Shalev, A. (2014). Minireview: Thioredoxin-interacting protein: regulation and function in the pancreatic β-cell. Molecular Endocrinology (Baltimore, Md.), 28(8), 1211–1220. http://doi.org/10.1210/me.2014-1095.

[27]

Wang, Y., Yuan, W., Guo, H., & Jiang, Y. (2015). High frequency of activated NKp46(+) natural killer cells in patients with new diagnosed of latent autoimmune diabetes in adults. Autoimmunity,48(4),267–273. http://doi.org/10.3109/08916934.2014.990629.

[28]

Xu, G., Chen, J., Jing, G., & Shalev, A. (2012). Preventing β-cell loss and diabetes with calcium channel blockers. Diabetes, 61(4), 848–856. http://doi.org/10.2337/db11-0955.

[29]

Zhao, Y., Li, X., & Tang, S. (2015). Retrospective analysis of the relationship between elevated plasma levels of TXNIP and carotid intima-media thickness in subjects with impaired glucose tolerance and early Type 2 diabetes mellitus. Diabetes Research and Clinical Practice, 109(2), 372–377. http://doi.org/10.1016/j.diabres.2015.05.028.

[30]

Winer, D. A., Winer, S., Chng, M. H. Y., Shen, L., & Engleman, E. G. (2014). B Lymphocytes in obesity-related adipose tissue inflammation and insulin resistance. Cellular and Molecular Life Sciences: CMLS, 71(6), 1033–1043. http://doi.org/10.1007/s00018-013-1486-y.

[31]

Shen, L., Chng, M. H. Y., Alonso, M. N., Yuan, R., Winer, D. A., & Engleman, E. G. (2015). B-1a lymphocytes attenuate insulin resistance. Diabetes, 64(2), 593–603. http://doi.org/10.2337/db14-0554

[32]

Cardoso-Sánchez, L. I., Gómez-Díaz, R. A., & Wacher, N. H. (2015). Vitamin D intake associates with insulin resistance in type 2 diabetes, but not in latent autoimmune diabetes in adults. Nutrition Research (New York, N.Y.), 35(8), 689–699. http://doi.org/10.1016/j.nutres.2015.05.019

[33]

Cernea, S., Buzzetti, R., & Pozzilli, P. (2009). β-Cell Protection and Therapy for Latent Autoimmune Diabetes in Adults. Diabetes Care, 32(suppl 2), S246–S252. http://doi.org/10.2337/dc09-S317.

[34]

Cheng, L., Zhang, D., Jiang, Y., Deng, W., Wu, Q., Jiang, X., & Chen, B. (2014). Decreased A20 mRNA and protein expression in peripheral blood mononuclear cells in patients with type 2 diabetes and latent autoimmune diabetes in adults. Diabetes Research And Clinical Practice, 106(3), 611–616. http://doi.org/10.1016/j.diabres.2014.09.014.

[35]

Hernandez, M., Mollo, A., Marsal, J. Ramon, Esquerda, A., Capel, I., Puig-Domingo, M., … Mauricio, D. (2015). Insulin secretion in patients with latent autoimmune diabetes (LADA): half way between type 1 and type 2 diabetes: action LADA 9. BMC Endocrine Disorders, 15(1), 1–13. http://doi.org/10.1186/1472-6823-15-1.

[36]

Hossein, G. M., Maryam, S., Saeed, E., Hamid, N., & Mahdieh, M. (2015). The prevalence of latent autoimmune diabetes in adults and its correlates in patients with type 2 diabetes in Kerman, Iran [2011]. Diabetes & Meolic Syndrome, 9(2), 104–107. http://doi.org/10.1016/j.dsx.2014.04.014

[37]

Krause, S., Landherr, U., Agardh, C.-D., Hausmann, S., Link, K., Hansen, J., M., … Achenbach, P. (2014). GAD Autoantibody Affinity in Adult Patients With Latent Autoimmune Diabetes, the Study Participants of a GAD65 Vaccination Trial. Diabetes Care, 37(6), 1675–1680. http://doi.org/10.2337/dc13-1719

[38]

Löfvenborg, J. E., Andersson, T., Carlsson, P.-O., Dorkhan, M., Groop, L., Martinell, M., … Carlsson, S. (2014). Coffee consumption and the risk of latent autoimmune diabetes in adults--results from a Swedish case-control study. Diabetic Medicine: A Journal Of The British Diabetic Association, 31(7), 799–805. http://doi.org/10.1111/dme.12469

[39]

Rasouli, B., Andersson, T., Carlsson, P.-O., Dorkhan, M., Grill, V., Groop, L., … Carlsson, S. (2014). Alcohol and the risk for latent autoimmune diabetes in adults: results based on Swedish ESTRID study. European Journal Of Endocrinology / European Federation Of Endocrine Societies, 171(5), 535–543. http://doi.org/10.1530/EJE-14-0403

[40]

Rolandsson, O., & Palmer, J. P. (2010). Latent autoimmune diabetes in adults (LADA) is dead: long live autoimmune diabetes! Diabetologia, 53(7), 1250–1253. http://doi.org/10.1007/s00125-010-1713-0